UK Center Installs Protein Purification Technology

Article

The UK’s National Biologics Manufacturing Centre will use Novasep’s BioSC Lab for protein purification.

The Centre for Process Innovation (CPI), a UK-based technology innovation center that provides services to small and medium-sized enterprises in the UK, has equipped the UK National Biologics Manufacturing Centre with Novasep’s BioSC Lab for protein purification. CPI’s services are intended to decrease time to market for novel products or processes. Within this framework, the CPI has been keen to introduce breakthrough continuous processes in the UK biopharmaceutical sector, CPI said in a press release. These technologies enable developers to reduce equipment footprint and increase process yields, thereby saving time and money.

“The National Biologics Manufacturing Centre has been designed to help companies of all sizes to develop, prove, and commercialize new and improved processes and technologies for biopharmaceutical manufacture,” said Chris Dowle, director of biologics at CPI, in the release. “The installation of Novasep’s BioSC Lab will be a valuable asset to customers using the centre."

Novasep’s continuous biochromatography equipment, BiosSC Lab, can purify a few grams of proteins per day. This enables users to develop cost-effective, high-yield production processes while maintaining the same quality attributes of the protein. The equipment is flexible and supports any process operating mode, including batch, parallel batch, and continuous. It is specifically designed to quickly provide the operator with the best operational parameters for purifying and converting a batch biochromatography recipe into a continuous, optimized one. Its simulation software, BioSC Predict, frees the process developer to set the most efficient mode and parameters to purify biomolecules such as monoclonal antibodies (mAbs), blood factors, and other proteins.

Source: Novasep

Recent Videos
Behind the Headlines, episode 7
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content